Prevalence, Clinical Severity, and Seasonality of Adenovirus 40/41, Astrovirus, Sapovirus, and Rotavirus Among Young Children With Moderate-to-Severe Diarrhea: Results From the Vaccine Impact on Diarrhea in Africa (VIDA) Study.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
19 04 2023
Historique:
medline: 21 4 2023
pubmed: 19 4 2023
entrez: 19 04 2023
Statut: ppublish

Résumé

While rotavirus causes severe diarrheal disease in children aged <5 years, data on other viral causes in sub-Saharan Africa are limited. In the Vaccine Impact on Diarrhea in Africa study (2015-2018), we analyzed stool from children aged 0-59 months with moderate-to-severe diarrhea (MSD) and without diarrhea (controls) in Kenya, Mali, and The Gambia using quantitative polymerase chain reaction. We derived the attributable fraction (AFe) based on the association between MSD and the pathogen, accounting for other pathogens, site, and age. A pathogen was attributable if the AFe was ≥0.5.The severity of attributable MSD was defined by a modified Vesikari score (mVS). Monthly cases were plotted against temperature and rainfall to assess seasonality. Among 4840 MSD cases, proportions attributed to rotavirus, adenovirus 40/41, astrovirus, and sapovirus were 12.6%, 2.7%, 2.9%, and 1.9%, respectively. Attributable rotavirus, adenovirus 40/41, and astrovirus MSD cases occurred at all sites, with mVS of 11, 10, and 7, respectively. MSD cases attributable to sapovirus occurred in Kenya, with mVS of 9. Astrovirus and adenovirus 40/41 peaked during the rainy season in The Gambia, while rotavirus peaked during the dry season in Mali and The Gambia. In sub-Saharan Africa, rotavirus was the most common cause of MSD; adenovirus 40/41, astrovirus, and sapovirus contributed to a lesser extent among children aged <5 years. Rotavirus- and adenovirus 40/41-attributable MSD were most severe. Seasonality varied by pathogen and location. Efforts to increase the coverage of rotavirus vaccines and to improve prevention and treatment for childhood diarrhea should continue.

Sections du résumé

BACKGROUND
While rotavirus causes severe diarrheal disease in children aged <5 years, data on other viral causes in sub-Saharan Africa are limited.
METHODS
In the Vaccine Impact on Diarrhea in Africa study (2015-2018), we analyzed stool from children aged 0-59 months with moderate-to-severe diarrhea (MSD) and without diarrhea (controls) in Kenya, Mali, and The Gambia using quantitative polymerase chain reaction. We derived the attributable fraction (AFe) based on the association between MSD and the pathogen, accounting for other pathogens, site, and age. A pathogen was attributable if the AFe was ≥0.5.The severity of attributable MSD was defined by a modified Vesikari score (mVS). Monthly cases were plotted against temperature and rainfall to assess seasonality.
RESULTS
Among 4840 MSD cases, proportions attributed to rotavirus, adenovirus 40/41, astrovirus, and sapovirus were 12.6%, 2.7%, 2.9%, and 1.9%, respectively. Attributable rotavirus, adenovirus 40/41, and astrovirus MSD cases occurred at all sites, with mVS of 11, 10, and 7, respectively. MSD cases attributable to sapovirus occurred in Kenya, with mVS of 9. Astrovirus and adenovirus 40/41 peaked during the rainy season in The Gambia, while rotavirus peaked during the dry season in Mali and The Gambia.
CONCLUSIONS
In sub-Saharan Africa, rotavirus was the most common cause of MSD; adenovirus 40/41, astrovirus, and sapovirus contributed to a lesser extent among children aged <5 years. Rotavirus- and adenovirus 40/41-attributable MSD were most severe. Seasonality varied by pathogen and location. Efforts to increase the coverage of rotavirus vaccines and to improve prevention and treatment for childhood diarrhea should continue.

Identifiants

pubmed: 37074439
pii: 7130320
doi: 10.1093/cid/ciad060
pmc: PMC10116545
doi:

Substances chimiques

Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

S123-S131

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Déclaration de conflit d'intérêts

Potential conflicts of interest. E. R. H. reports funding from the Bill & Melinda Gates Foundation. K. L. K. reports consultation fees and travel support from PATH and the University of Washington related to diarrheal diseases and grant support to her institution from the National Institutes of Health, Institut Pasteur, and the Bill & Melinda Gates Foundation. S. M. T. reports multiple grants paid to her institution from the National Institutes of Health, Bill & Melinda Gates Foundation, Wellcome Trust, Affinivax, Lumen Biosciences, PATH, and Medical Research Council; payments as royalties related to intellectual property for Salmonella vaccines and Klebsiella/Pseudomonas vaccines; consulting fees and travel support from the University of Washington for a grant proposal; holding multiple planned, issued, and pending patents on Salmonella, Klebsiella, and Pseudomonas vaccines; and holding multiple unpaid committee roles with the American Society of Tropical Medicine and Hygiene. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Références

N Engl J Med. 2013 Mar 21;368(12):1121-30
pubmed: 23514289
PLoS Med. 2016 Apr 26;13(4):e1001999
pubmed: 27115709
Clin Infect Dis. 2012 Dec;55 Suppl 4:S232-45
pubmed: 23169936
Clin Infect Dis. 2019 Jul 2;69(2):243-250
pubmed: 30335135
Clin Infect Dis. 2023 Apr 19;76(Supplement_1):S5-S11
pubmed: 37074428
Biomedicines. 2019 Aug 19;7(3):
pubmed: 31430920
J Infect Dis. 2020 Oct 13;222(10):1731-1739
pubmed: 32095831
Lancet Infect Dis. 2014 Aug;14(8):716-724
pubmed: 25022434
Lancet Child Adolesc Health. 2019 Nov;3(11):758-759
pubmed: 31439497
Lancet. 2010 Aug 21;376(9741):615-23
pubmed: 20692031
Clin Infect Dis. 2012 Dec;55 Suppl 4:S246-53
pubmed: 23169937
Pediatr Clin North Am. 2017 Aug;64(4):799-814
pubmed: 28734511
Lancet. 2021 Sep 4;398(10303):870-905
pubmed: 34416195
N Engl J Med. 2010 Jan 28;362(4):289-98
pubmed: 20107214
Lancet. 2017 Sep 16;390(10100):1151-1210
pubmed: 28919116
Eur J Pediatr. 2013 Jun;172(6):739-46
pubmed: 23361964
Clin Infect Dis. 2021 Feb 16;72(4):576-585
pubmed: 32009161
Vaccine. 2012 Apr 27;30 Suppl 1:A24-9
pubmed: 22520132
Sci Rep. 2019 Jan 30;9(1):929
pubmed: 30700747
Lancet Glob Health. 2018 Dec;6(12):e1309-e1318
pubmed: 30287127
Vaccine. 2022 Mar 15;40(12):1707-1711
pubmed: 35184924
Pediatr Infect Dis J. 2014 Nov;33(11):1156-63
pubmed: 24879131
Clin Infect Dis. 2021 Nov 2;73(9):e2493-e2499
pubmed: 32592580
Mem Inst Oswaldo Cruz. 2014 Jul;109(4):428-35
pubmed: 25075782
Pathogens. 2020 Aug 15;9(8):
pubmed: 32824245
Lancet. 2013 Jul 20;382(9888):209-22
pubmed: 23680352
Lancet. 2016 Sep 24;388(10051):1291-301
pubmed: 27673470
Clin Infect Dis. 2012 Dec;55 Suppl 4:S294-302
pubmed: 23169941
Clin Microbiol Infect. 2016 Apr;22(4):381.e9-381.e16
pubmed: 26724990
J Pediatric Infect Dis Soc. 2013 Mar;2(1):57-60
pubmed: 23687584
Lancet Glob Health. 2019 May;7(5):e568-e584
pubmed: 31000128
Pediatrics. 2022 Jan 1;149(1):
pubmed: 34918158
Pediatrics. 1989 Aug;84(2):219-25
pubmed: 2546121
Lancet Glob Health. 2018 Dec;6(12):e1319-e1328
pubmed: 30287125
Clin Infect Dis. 2023 Apr 19;76(Supplement_1):S114-S122
pubmed: 37074441
Pediatrics. 2018 Jan;141(1):
pubmed: 29259078
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326

Auteurs

Adama Mamby Keita (AM)

Centre pour le Développement des Vaccins du Mali (CVD-Mali), Bamako, Mali.

Sanogo Doh (S)

Centre pour le Développement des Vaccins du Mali (CVD-Mali), Bamako, Mali.

Samba O Sow (SO)

Centre pour le Développement des Vaccins du Mali (CVD-Mali), Bamako, Mali.

Helen Powell (H)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Richard Omore (R)

Kenya Medical Research Institute, Center for Global Health Research (KEMRI-CGHR), Kisumu, Kenya.

M Jahangir Hossain (M)

Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.

Billy Ogwel (B)

Kenya Medical Research Institute, Center for Global Health Research (KEMRI-CGHR), Kisumu, Kenya.

John B Ochieng (JB)

Kenya Medical Research Institute, Center for Global Health Research (KEMRI-CGHR), Kisumu, Kenya.

Joquina Chiquita M Jones (JCM)

Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.

Syed M A Zaman (SMA)

Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.

Alex O Awuor (AO)

Kenya Medical Research Institute, Center for Global Health Research (KEMRI-CGHR), Kisumu, Kenya.

Jane Juma (J)

Kenya Medical Research Institute, Center for Global Health Research (KEMRI-CGHR), Kisumu, Kenya.

Dilruba Nasrin (D)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Jie Liu (J)

Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Charlottesville, Virginia, USA.

Awa Traoré (A)

Centre pour le Développement des Vaccins du Mali (CVD-Mali), Bamako, Mali.

Uma Onwuchekwa (U)

Centre pour le Développement des Vaccins du Mali (CVD-Mali), Bamako, Mali.

Henry Badji (H)

Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.

Golam Sarwar (G)

Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.

Martin Antonio (M)

Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.

Eric R Houpt (ER)

Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Charlottesville, Virginia, USA.

Sharon M Tennant (SM)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Irene N Kasumba (IN)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Leslie P Jamka (LP)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Anna Roose (A)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA.

James A Platts-Mills (JA)

Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Charlottesville, Virginia, USA.

Jennifer R Verani (JR)

Division of Global Health Protection, US Centers for Disease Control and Prevention, Nairobi, Kenya.

Jacqueline E Tate (JE)

Division of Viral Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Umesh D Parashar (UD)

Division of Viral Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Kathleen M Neuzil (KM)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Karen L Kotloff (KL)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH